Changeflow GovPing Healthcare Funding HRSA 340B Rebate Model Pilot Program Applicatio...
Priority review Consultation Added Consultation

HRSA 340B Rebate Model Pilot Program Application and Comment Period

Favicon for www.hrsa.gov HRSA News
Published July 31st, 2025
Detected March 13th, 2026
Email

Summary

The Health Resources and Services Administration (HRSA) has announced a voluntary 340B Rebate Model Pilot Program for 2026 drugs. HRSA is seeking public comment on the application process for manufacturers and the pilot program itself, with a 30-day comment period.

What changed

The Health Resources and Services Administration (HRSA) is launching a voluntary 340B Rebate Model Pilot Program for drugs on the CMS Medicare Drug Price Negotiation Selected Drug List for 2026. This pilot aims to test a rebate model in a structured manner to assess its merits and shortcomings from the perspective of both covered entities and manufacturers. The program is designed to inform future rebate models under the 340B statute.

Manufacturers meeting specific criteria can apply to participate in the pilot program. HRSA is also requesting public comment on the application process and the pilot program itself, with a 30-day comment period following the Federal Register Notice. Affected parties, including drug manufacturers and healthcare providers (covered entities), should review the Federal Register Notice for details on submitting applications and comments.

What to do next

  1. Review the Federal Register Notice regarding the 340B Rebate Model Pilot Program.
  2. Submit comments on the application process and pilot program within the 30-day comment period.
  3. Manufacturers meeting criteria should consider applying to participate in the pilot program.

Source document (simplified)

HRSA Announces Application Process for the 340B Rebate Model Pilot Program and Request for Public Comment

U.S. Department of Health and Human Services
Health Resources and Services Administration For Immediate Release

July 31, 2025

HRSA News Room newsroom.hrsa.gov Contact: HRSA PRESS OFFICE Phone: 301-443-7070 Media Inquiries: Submit via this form Today, the Health Resources and Services Administration (HRSA) announced the availability of a voluntary 340B Rebate Model Pilot Program for drugs on the CMS Medicare Drug Price Negotiation Selected Drug List for year 2026 from qualifying manufacturers meeting specific criteria.

HRSA is introducing this pilot program to test the rebate model on these drugs in a methodical and thoughtful approach to ensure a fair and transparent 340B rebate model process.  HRSA is implementing this pilot to better understand the merits and shortcomings of the rebate model from the perspective of affected stakeholders, and to help shape any future 340B rebate models that align with the 340B statute and the Administration’s goals.

“The 340B Program provides vital healthcare access for high-need communities by allowing health care providers – also known as covered entities – to purchase medications at reduced prices,” said HRSA Administrator Tom Engels. “Today’s announcement of the availability of a Rebate Model Pilot Program addresses concerns we have received from both covered entities and manufacturers, while creating a measured approach to the process of approving manufacturer rebate models under the 340B Program. We look forward to receiving comments and working with everyone to ensure that the program operates with accountability, transparency and adherence to the 340B statute, allowing covered entities to stretch scarce resources as far as possible.”

For more information on how to submit a Rebate Model Pilot plan or to provide comments during the 30-day comment period please visit the 340B Program Notice: Application Process for the 340B Rebate Model Pilot Program Federal Register Notice (PDF - 240 KB).

Date Last Reviewed:

July 2025

Back to Listing

Get HRSA Press Releases In Your Inbox

NOTE: You will only get HRSA press releases through our email list. To receive HHS press releases about HRSA, sign up with HHS.

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
Various Federal Agencies
Published
July 31st, 2025
Instrument
Consultation
Legal weight
Non-binding
Stage
Consultation
Change scope
Substantive

Who this affects

Applies to
Drug manufacturers Healthcare providers
Geographic scope
National (US)

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Compliance
Topics
Healthcare Access Drug Pricing

Get Healthcare Funding alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when HRSA News publishes new changes.

Free. Unsubscribe anytime.